Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system

Human Pathology

Volumn 40, Issue 11, 2009, Pages 1571-1585

  D'Angelo, Emanuela ^a   Spagnoli, Luigi G ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

bcl 2; Endometrial stromal sarcoma; Immunohistochemistry; Ki67; Leiomyosarcoma; p16; p53; Twist; Undifferentiated endometrial sarcoma; Uterine sarcomas; WHO

Indexed keywords

CALDESMON; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; DISEASE CLASSIFICATION; ENDOMETRIUM SARCOMA; FEMALE; FOLLOW UP; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; OUTCOME ASSESSMENT; SMOOTH MUSCLE; TISSUE MICROARRAY; UNDIFFERENTIATED ENDOMETRIAL SARCOMA; UTERUS SARCOMA; WORLD HEALTH ORGANIZATION;

AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SARCOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 70349852614     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.03.018     Document Type: Article

References (41)

1. Gadducci A., Landoni F., Sartori E., et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 62 (1996) 25-32
2. Gadducci A., Sartori E., Landoni F., et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63 (1996) 247-253
3. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 71 (1993) 1702-1709
4. Giuntoli II R.L., and Bristow R.E. Uterine leiomyosarcoma: present management. Curr Opin Oncol 16 (2004) 324-327
5. McCluggage W.G., Haller U., Kurman R.J., and Kubick-Huch R.A. Mixed epithelial and mesenchymal tumours. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs (2003), IARC Press, Lyon 245-249
6. Bell S.W., Kempson R.L., and Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18 (1994) 535-558
7. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89 (2003) 460-469
8. Wang W.L., Soslow R.A., Hensley M., et al. Histopathologic prognostic factors in stage I uterine leiomyosarcomas (Ut-LMS): a clinicopathologic study of 28 cases. [abstract]. Mod Path 217A (2007)
9. Chang K.L., Crabtree G.S., Lim-Tan S.K., Kempson R.L., and Hendrickson M.R. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 14 (1990) 415-438
10. Denschlag D., Masoud I., Stanimir G., and Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 33 (2007) 91-95
11. Abeler V.M., Røyne O., Thoresen S., Danielsen H.E., Nesland J.M., and Kristensen G.B. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 54 (2009) 355-364
12. Kapp D.S., Shin J.Y., and Chan J.K. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112 (2008) 820-830
13. Koivisto-Korander R., Butzow R., Koivisto A.M., and Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol 111 (2008) 74-81
14. Kurihara S., Oda Y., Ohishi Y., et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32 (2008) 1228-1238
15. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104 (2009) 179
16. Akhan S.E., Yavuz E., Tecer A., et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 99 (2005) 36-42
17. Atkins K.A., Arronte N., Darus C.J., and Rice L.W. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 32 (2008) 98-102
18. Bodner K., Bodner-Adler B., Kimberger O., Czerwenka K., and Mayerhofer K. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 11 (2004) 187-191
19. Bodner-Adler B., Bodner K., Czerwenka K., Kimberger O., Leodolter S., and Mayerhofer K. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 96 (2005) 62-66
20. Chen L., and Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 27 (2008) 326-332
21. Jeffers M.D., Farquharson M.A., Richmond J.A., and McNicol A.M. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 177 (1995) 65-70
22. Mayerhofer K., Obermair A., Windbichler G., et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74 (1999) 196-201
23. Mittal K., and Demopoulos R.I. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 32 (2001) 984-987
24. Niemann T.H., Raab S.S., Lenel J.C., Rodgers J.R., and Robinson R.A. P53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 26 (1995) 375-379
25. O'Neill C.J., McBride H.A., Connolly L.E., and McCluggage W.G. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50 (2007) 851-858
26. Zhai Y.L., Kobayashi Y., Mori A., et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 18 (1999) 20-28
27. Hendrickson M.R., Tavassoli F.A., Kempson R.L., Mc Cluggage W.G., Haller U., and Kubik-Huch R.A. Mesenchymal tumours and related lesions. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon 233-244
28. Atkins K.A., Bell M.E., Kempson R., and Hendrickson M. Myxoid smooth muscle tumors of the uterus. Mod Pathol 14 (2001) 132A
29. Nocito A., Kononen J., Kallioniemi O.P., and Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 94 (2001) 1-5
30. Liu C.L., Montgomery K.D., Natkunam Y., et al. TMA-combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol 18 (2005) 1641-1648
31. Liu C.L., Prapong W., Natkunam Y., et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 161 (2002) 1557-1565
32. Jones M.W., and Norris H.J. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 14 (1995) 243-249
33. Anderson S.E., Nonaka D., Chuai S., et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer 16 (2006) 849-853
34. Skubitz K.M., and Skubitz A.P. Differential gene expression in leiomyosarcoma. Cancer 98 (2003) 1029-1038
35. Maestro R., Dei Tos A.P., Hamamori Y., et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13 (1999) 2207-2217
36. Evan G.I., Wyllie A.H., Gilbert C.S., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 (1992) 119-128
37. Zindy F., Eischen C.M., Randle D.H., et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12 (1998) 2424-2433
38. Shiota M., Izumi H., Onitsuka T., et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene (2008) [Epub ahead of print]
39. Jeffers M.D., Richmond J.A., and Macaulay E.M. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 8 (1995) 701-704
40. Nucci M.R., O'Connell J.T., Huettner P.C., Cviko A., Sun D., and Quade B.J. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 25 (2001) 455-463
41. Chu P.G., Arber D.A., Weiss L.M., and Chang K.L. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 14 (2001) 465-471